These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 36813172)

  • 1. Preclinical trial comparing radiotherapy alone versus standard radiochemotherapy in three human papilloma virus (HPV) negative and three HPV-positive head and neck squamous cell carcinoma (HNSCC) xenograft tumour models.
    Valentini C; Ebert N; Koi L; Pfeifer M; Löck S; Erdmann C; Krause M; Baumann M
    Radiother Oncol; 2023 Jun; 183():109546. PubMed ID: 36813172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EGFR overexpression increases radiotherapy response in HPV-positive head and neck cancer through inhibition of DNA damage repair and HPV E6 downregulation.
    Alsahafi EN; Thavaraj S; Sarvestani N; Novoplansky O; Elkabets M; Ayaz B; Tavassoli M; Legends MF
    Cancer Lett; 2021 Feb; 498():80-97. PubMed ID: 33137407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human papillomavirus associated XPF deficiency increases alternative end joining and cisplatin sensitivity in head and neck squamous cell carcinoma.
    Zuo N; Ma L; Liu T; Hu W; Luo Y; Meng H; Ren Q; Deng Y; Wei L; Liu Q
    Oral Oncol; 2023 May; 140():106367. PubMed ID: 36996606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypofractionated radiotherapy alone with 2.4 Gy per fraction for head and neck cancer during the COVID-19 pandemic: The Princess Margaret experience and proposal.
    Huang SH; O'Sullivan B; Su J; Ringash J; Bratman SV; Kim J; Hosni A; Bayley A; Cho J; Giuliani M; Hope A; Spreafico A; Hansen AR; Siu LL; Gilbert R; Irish JC; Goldstein D; de Almeida J; Tong L; Xu W; Waldron J
    Cancer; 2020 Aug; 126(15):3426-3437. PubMed ID: 32478895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease outcome and associated factors after definitive platinum based chemoradiotherapy for advanced stage HPV-negative head and neck cancer.
    de Roest RH; van der Heijden M; Wesseling FWR; de Ruiter EJ; Heymans MW; Terhaard C; Vergeer MR; Buter J; Devriese LA; de Boer JP; Navran A; Hoeben A; Vens C; van den Brekel M; Brakenhoff RH; Leemans CR; Hoebers F
    Radiother Oncol; 2022 Oct; 175():112-121. PubMed ID: 35973619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiotherapy combined with docetaxel alters the immune phenotype of HNSCC cells and results in increased surface expression of CD137 and release of HMGB1 of specifically HPV-positive tumor cells.
    Grottker F; Gehre S; Reichardt CM; Sengedorj A; Jost T; Rieckmann T; Hecht M; Gostian AO; Frey B; Fietkau R; Gaipl US; Rückert M
    Neoplasia; 2023 Nov; 45():100944. PubMed ID: 37857049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic biomarkers for the response to the radiosensitizer nimorazole combined with RCTx: a pre-clinical trial in HNSCC xenografts.
    Koi L; Bitto V; Weise C; Möbius L; Linge A; Löck S; Yaromina A; Besso MJ; Valentini C; Pfeifer M; Overgaard J; Zips D; Kurth I; Krause M; Baumann M
    J Transl Med; 2023 Aug; 21(1):576. PubMed ID: 37633930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic implications of transcriptomics in head and neck cancer patient-derived xenografts.
    Lee RH; Roy R; Li H; Hechmer A; Zhu TR; Izgutdina A; Olshen AB; Johnson DE; Grandis JR
    PLoS One; 2023; 18(3):e0282177. PubMed ID: 36857322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Computed Tomography Radiomics Predicts HPV Status and Local Tumor Control After Definitive Radiochemotherapy in Head and Neck Squamous Cell Carcinoma.
    Bogowicz M; Riesterer O; Ikenberg K; Stieb S; Moch H; Studer G; Guckenberger M; Tanadini-Lang S
    Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):921-928. PubMed ID: 28807534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical Evaluation of the ATR Inhibitor BAY 1895344 as a Radiosensitizer for Head and Neck Squamous Cell Carcinoma.
    Odhiambo DA; Pittman AN; Rickard AG; Castillo RJ; Bassil AM; Chen J; Ravotti ML; Xu ES; Himes JE; Daniel AR; Watts TL; Williams NT; Luo L; Kirsch DG; Mowery YM
    Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1315-1327. PubMed ID: 38104870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGFR-amplification plus gene expression profiling predicts response to combined radiotherapy with EGFR-inhibition: A preclinical trial in 10 HNSCC-tumour-xenograft models.
    Koi L; Löck S; Linge A; Thurow C; Hering S; Baumann M; Krause M; Gurtner K
    Radiother Oncol; 2017 Sep; 124(3):496-503. PubMed ID: 28807520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Polo-like kinase 1 inhibitor onvansertib represents a relevant treatment for head and neck squamous cell carcinoma resistant to cisplatin and radiotherapy.
    Hagege A; Ambrosetti D; Boyer J; Bozec A; Doyen J; Chamorey E; He X; Bourget I; Rousset J; Saada E; Rastoin O; Parola J; Luciano F; Cao Y; Pagès G; Dufies M
    Theranostics; 2021; 11(19):9571-9586. PubMed ID: 34646387
    [No Abstract]   [Full Text] [Related]  

  • 13. Palbociclib-based high-throughput combination drug screening identifies synergistic therapeutic options in HPV-negative head and neck squamous cell carcinoma.
    Gu Z; Shi C; Li J; Han Y; Sun B; Zhang W; Wu J; Zhou G; Ye W; Li J; Zhang Z; Zhou R
    BMC Med; 2022 May; 20(1):175. PubMed ID: 35546399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of post-operative radiotherapy with concurrent cisplatin plus panitumumab in patients with high-risk, resected head and neck cancer.
    Ferris RL; Geiger JL; Trivedi S; Schmitt NC; Heron DE; Johnson JT; Kim S; Duvvuri U; Clump DA; Bauman JE; Ohr JP; Gooding WE; Argiris A
    Ann Oncol; 2016 Dec; 27(12):2257-2262. PubMed ID: 27733374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. nab-Paclitaxel-based induction chemotherapy followed by cisplatin and radiation therapy for human papillomavirus-unrelated head and neck squamous-cell carcinoma.
    Johnson KCC; Ley J; Oppelt P; Lu J; Gay HA; Daly M; Jackson R; Rich J; Pipkorn P; Paniello RC; Zevallos J; Thorstad W; Adkins DR
    Med Oncol; 2019 Oct; 36(11):93. PubMed ID: 31595355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concurrent weekly cisplatin and simultaneous integrated boost intensity-modulated radiotherapy of locally advanced squamous cell carcinoma of the head and neck.
    Dubinský P; Jeremic B; Švajdová M; Barilíková G; Matula P; Nadzonová D; Vojtek V
    Klin Onkol; 2022; 35(4):307-314. PubMed ID: 35989088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ATR inhibition sensitizes HPV
    Leonard BC; Lee ED; Bhola NE; Li H; Sogaard KK; Bakkenist CJ; Grandis JR; Johnson DE
    Oral Oncol; 2019 Aug; 95():35-42. PubMed ID: 31345392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Locally advanced head and neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. Results from the DAHANCA 18 phase II study.
    Bentzen J; Toustrup K; Eriksen JG; Primdahl H; Andersen LJ; Overgaard J
    Acta Oncol; 2015 Jul; 54(7):1001-7. PubMed ID: 25629651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human papillomavirus-associated head and neck squamous cell carcinoma survival: a comparison by tumor site and initial treatment.
    Salazar CR; Smith RV; Garg MK; Haigentz M; Schiff BA; Kawachi N; Anayannis N; Belbin TJ; Prystowsky MB; Burk RD; Schlecht NF
    Head Neck Pathol; 2014 Mar; 8(1):77-87. PubMed ID: 24002971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamic changes of the EMT spectrum between circulating tumor cells and the tumor microenvironment in human papillomavirus-positive head and neck squamous cell carcinoma.
    Ida S; Takahashi H; Tada H; Mito I; Matsuyama T; Chikamatsu K
    Oral Oncol; 2023 Feb; 137():106296. PubMed ID: 36571985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.